Geron Corporation (BIT:1GERN)

Italy flag Italy · Delayed Price · Currency is EUR
1.205
0.00 (0.00%)
At close: Jul 18, 2025
Market Cap721.73M
Revenue (ttm)107.59M
Net Income (ttm)-128.62M
Shares Outn/a
EPS (ttm)-0.19
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Openn/a
Previous Close1.205
Day's Rangen/a
52-Week Range1.205 - 1.390
Betan/a
RSI6.27
Earnings DateAug 7, 2025

About Geron

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1990
Employees 229
Stock Exchange Borsa Italiana
Ticker Symbol 1GERN
Full Company Profile

Financial Performance

In 2024, Geron's revenue was $76.99 million, an increase of 32386.92% compared to the previous year's $237,000. Losses were -$174.57 million, -5.19% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.